These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10428912)

  • 1. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus.
    Aeschlimann JR; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1914-8. PubMed ID: 10428912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of reduced vancomycin susceptibility of MRSA strain Mu50 with various conditions of antibiotic susceptibility tests].
    Hanaki H; Hiramatsu K
    Jpn J Antibiot; 1997 Sep; 50(9):794-8. PubMed ID: 9394239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
    Hiramatsu K; Aritaka N; Hanaki H; Kawasaki S; Hosoda Y; Hori S; Fukuchi Y; Kobayashi I
    Lancet; 1997 Dec; 350(9092):1670-3. PubMed ID: 9400512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of vancomycin-intermediate-resistant Staphylococcus aureus in Japan.
    Hanaki H; Hososaka Y; Yanagisawa C; Otsuka Y; Nagasawa Z; Nakae T; Sunakawa K
    J Infect Chemother; 2007 Apr; 13(2):118-21. PubMed ID: 17458681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Houlihan HH; Rybak MJ
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1307-12. PubMed ID: 9174189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Stumpo C; Rybak MJ
    J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.
    Climo MW; Patron RL; Archer GL
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1747-53. PubMed ID: 10390234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination effect of vancomycin and cefpirome against methicillin-resistant Staphylococcus aureus in vitro--antimicrobial activities in postantibiotic phase].
    Hasegawa H; Kanai A; Otoguro K; Shimizu K
    Kansenshogaku Zasshi; 1996 Feb; 70(2):151-60. PubMed ID: 8851387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.
    Ike Y; Arakawa Y; Ma X; Tatewaki K; Nagasawa M; Tomita H; Tanimoto K; Fujimoto S
    J Clin Microbiol; 2001 Dec; 39(12):4445-51. PubMed ID: 11724859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.
    Hanaki H; Kuwahara-Arai K; Boyle-Vavra S; Daum RS; Labischinski H; Hiramatsu K
    J Antimicrob Chemother; 1998 Aug; 42(2):199-209. PubMed ID: 9738837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 May; 44(5):1153-8. PubMed ID: 10770744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis.
    Löwdin E; Odenholt I; Cars O
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2739-44. PubMed ID: 9756787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of laboratory-generated vancomycin intermediate resistant Staphylococcus aureus strains.
    Bhateja P; Purnapatre K; Dube S; Fatma T; Rattan A
    Int J Antimicrob Agents; 2006 Mar; 27(3):201-11. PubMed ID: 16417988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo development of decreased susceptibility to vancomycin in clinical isolates of methicillin-resistant Staphylococcus aureus.
    Sugino Y; Iinumab Y; Ichiyama S; Ito Y; Ohkawa S; Nakashima N; Shimokata K; Hasegawa Y
    Diagn Microbiol Infect Dis; 2000 Nov; 38(3):159-67. PubMed ID: 11109014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.